Corteva (CTVA) Q4 FY25 earnings call

Corteva delivered a strong FY25 with significant organic growth and margin expansion, driven by differentiated technologies and operational efficiencies. The company also announced a comprehensive resolution with Bayer, accelerating its seed licensing ambitions and providing substantial long-term earnings upside. Looking ahead, Corteva reiterates its positive 2026 outlook, anticipating continued growth in sales and EBITDA despite ongoing market dynamics and planned separation activities.